KIT and neoplasm: Comparative analysis of the expression of the different tyrosine kinases that are targeted by the TKIs included in this work showed that c-Kit is more frequently expressed than the majority of targeted molecules in TNBC tumor samples; thus, c-Kit might be considered a potential marker for the treatment of TNBC using TKIs, in particular Nilotinib.